Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07220993CT.gov Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells | — | Recruiting | — | — | — |
NCT03690011CT.gov Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | — | Active Not Recruiting | — | — | — |
NCT03081910CT.gov Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd7.car/28zeta car t cells (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P1/2 | CCC · 54 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Asparaginase | University of Washington | P3 | BB |
| Dexasone | Children's Oncology Group | P3 | BB |
| Cyclophosphamide | Children's Oncology Group | P3 | BB |
| Thioguanine Anhydrous | Children's Oncology Group | P3 | BB |
| Mercaptopurine Anhydrous | Children's Oncology Group | P3 | BB |
| Methotrexate | Children's Oncology Group | P3 | BB |
+42 more in the T-Lymphoblastic Lymphoma cohort
Other indications for cd7.car/28zeta car t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P2 | BB · 66 |
| T-Cell Acute Lymphoblastic Leukemia | — | P1/2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd7.car/28zeta car t cells in T-Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd7car28zeta-car-t-cells-t-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →